ProPhase Labs (NASDAQ:PRPH) (NASDAQ:PRPH) is a U.S.-based life sciences company specializing in the development, manufacture and distribution of healthcare products across prescription, over-the-counter (OTC) and nutritional supplement markets. The company’s product portfolio encompasses cold and flu remedies, dietary supplements, functional gummy vitamins and rapid diagnostic solutions. Leveraging in-house research and development capabilities, ProPhase Labs designs proprietary formulations that address key consumer wellness needs, including immune support, digestive health and joint comfort.
ProPhase Labs operates two primary business segments. The product segment delivers branded and private-label nutraceuticals, OTC medications and food supplements through relationships with national retailers, specialty chains and e-commerce platforms. The licensing segment generates revenue by out-licensing intellectual property rights to generic drug manufacturers for select formulations. State-of-the-art production facilities in New Jersey and Florida support large-scale manufacturing, quality testing and regulatory compliance for both domestic and international customers.
Since its founding in the early 1980s, ProPhase Labs has evolved from a regional contract manufacturer into an integrated health-science organization. The company has secured multiple patents covering novel gummy delivery systems and botanical extracts, and continues to invest in advanced formulation science. Geographic reach extends beyond North America into Europe and Asia-Pacific markets through a network of distributors, strategic partnerships and online channels.
Under the leadership of Chief Executive Officer John Panichella, ProPhase Labs emphasizes operational agility, rigorous quality standards and innovation. The senior management team brings decades of combined experience in pharmaceutical development, nutraceutical marketing and diagnostic testing. This expertise has enabled the company to respond swiftly to shifting consumer trends and global health challenges while maintaining steady growth in its core supplement and OTC businesses.
